Pacira (PCRX) Rips Over 22% Following Q3 Results, EXPAREL FDA Approval

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/2/2026

1. SPY
2. MDT
3. USO
4. AAPL
5. SPGI

6. DELL
7. NIO
8. ENOV
9. AON
10. A

Price: $26.47 +2.20%

Overall Analyst Rating:
SELL (= Flat)

Pacira Pharmaceuticals (NASDAQ: PCRX) is ripping higher Monday morning, following strong Q3 results, and a new EXPAREL FDA approval.

The stock is up over 22 percent early.

Earnings

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!